Austar Lifesciences Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Mars Ho

Chief Executive Officer (CEO)

CN¥895.0k

Compensación total

Porcentaje del salario del CEO	98.3%
Permanencia del CEO	10.3yrs
Participación del CEO	67.0%
Permanencia media de la dirección	9.8yrs
Promedio de permanencia en la Junta Directiva	9.8yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mars Ho en comparación con los beneficios de Austar Lifesciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CN¥33m
Jun 30 2023	n/a	n/a	CN¥2m
Mar 31 2023	n/a	n/a	CN¥45m
Dec 31 2022	CN¥895k	CN¥880k	CN¥87m
Sep 30 2022	n/a	n/a	CN¥96m
Jun 30 2022	n/a	n/a	CN¥105m
Mar 31 2022	n/a	n/a	CN¥191m
Dec 31 2021	CN¥865k	CN¥850k	CN¥277m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥238m
Mar 31 2021	n/a	n/a	CN¥136m
Dec 31 2020	CN¥927k	CN¥911k	CN¥33m
Sep 30 2020	n/a	n/a	CN¥25m
Jun 30 2020	n/a	n/a	CN¥17m
Mar 31 2020	n/a	n/a	CN¥12m
Dec 31 2019	CN¥918k	CN¥902k	CN¥8m
Sep 30 2019	n/a	n/a	CN¥8m
Jun 30 2019	n/a	n/a	CN¥8m
Mar 31 2019	n/a	n/a	CN¥4m
Dec 31 2018	CN¥880k	CN¥865k	CN¥107k
Sep 30 2018	n/a	n/a	-CN¥16m
Jun 30 2018	n/a	n/a	-CN¥33m
Mar 31 2018	n/a	n/a	-CN¥43m
Dec 31 2017	CN¥1m	CN¥1m	-CN¥54m

Compensación vs. Mercado: Mars ($USD124.47K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD235.82K).

Compensación vs. Ingresos: La compensación de Mars ha aumentado mientras la empresa no es rentable.

CEO

Mars Ho (61 yo)

10.3yrs

Permanencia

CN¥895,000

Compensación

Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kwok Keung Ho	Founder	no data	CN¥895.00k	67% CN¥ 350.3m
Yuewu Chen	Executive Director	9.8yrs	CN¥1.47m	sin datos
Ning Zhou	Executive Director	9.8yrs	CN¥1.15m	sin datos
Kin Hung Ho	Executive Director	9.8yrs	CN¥2.40m	7.27% CN¥ 38.0m
Xiangdi Tang	Vice President of Corporate Development	3.3yrs	sin datos	sin datos
Yuk Kiu Mak	Company Secretary	1.5yrs	sin datos	sin datos

9.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: 6118El equipo directivo de la empresa es veterano y experimentado (9.7 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kwok Keung Ho	Founder	10.3yrs	CN¥895.00k	67% CN¥ 350.3m
Yuewu Chen	Executive Director	9.8yrs	CN¥1.47m	sin datos
Ning Zhou	Executive Director	9.8yrs	CN¥1.15m	sin datos
Kin Hung Ho	Executive Director	10.3yrs	CN¥2.40m	7.27% CN¥ 38.0m
Lap Kei Cheung	Independent Non-Executive Director	9.5yrs	CN¥155.00k	sin datos
Oi Kin Leung	Independent Non-Executive Director	6.5yrs	CN¥155.00k	sin datos
Hoi Shan Chiu	Independent Non-Executive Director	9.8yrs	CN¥155.00k	sin datos
Lingling Ji	Non-Executive Director	9.8yrs	CN¥648.00k	sin datos

9.8yrs

Permanencia media

50.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 6118 se considera experimentada (9.7 años de antigüedad promedio).

Austar Lifesciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Less than half of directors are independent

Recent updates

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Austar Lifesciences Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.063 loss per share (vs CN¥0.17 profit in FY 2022)

Austar Lifesciences Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

New major risk - Share price stability

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

First half 2023 earnings released: CN¥0.078 loss per share (vs CN¥0.089 profit in 1H 2022)

Investor sentiment deteriorates as stock falls 30%

Austar Lifesciences Limited to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.54 in FY 2021)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 25%

Austar Lifesciences Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Austar Lifesciences Limited Announces Executive Changes

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

First half 2022 earnings released: EPS: CN¥0.09 (vs CN¥0.42 in 1H 2021)

Investor sentiment deteriorated over the past week

Austar Lifesciences Limited to Report First Half, 2022 Results on Aug 29, 2022

Austar Lifesciences Limited (SEHK:6118) acquired an unknown minority interest in Noozle Fluid Technology (Shanghai) Co., Ltd..

Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Less than half of directors are independent

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Full year 2021 earnings released: EPS: CN¥0.54 (vs CN¥0.065 in FY 2020)

Investor sentiment improved over the past week

Austar Lifesciences Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorated over the past week

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

First half 2021 earnings released: EPS CN¥0.42 (vs CN¥0.025 in 1H 2020)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Full year 2020 earnings released: EPS CN¥0.065 (vs CN¥0.016 in FY 2019)

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.06 (vs CN¥0.016 in FY 2019)

Austar Lifesciences Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

An affiliate of Pall Corporation entered into an agreement to acquire 60% in PALL-AUSTAR Lifesciences Limited from Austar Lifesciences Limited (SEHK:6118) for approximately CNY 220 million.

New 90-day high: HK$6.15

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

New 90-day high: HK$4.02

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

First half earnings released

New 90-day low - HK$3.18

First half earnings released

Austar Lifesciences Limited to Report First Half, 2020 Results on Aug 27, 2020

New 90-day low - HK$3.23

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta